APTIVUS Drug Patent Profile

Which patents cover Aptivus, and when can generic versions of Aptivus launch?

Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. Additional details are available on the tipranavir profile page.

Summary for APTIVUS

US Patents:	0
Applicants:	1
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	7
Patent Applications:	7,393
Drug Prices:	Drug price information for APTIVUS
What excipients (inactive ingredients) are in APTIVUS?	APTIVUS excipients list
DailyMed Link:	APTIVUS at DailyMed

See drug prices for APTIVUS

Recent Clinical Trials for APTIVUS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Boehringer Ingelheim	Phase 3
National Institute of Mental Health (NIMH)	Phase 2/Phase 3
University of California, San Diego	Phase 2/Phase 3

See all APTIVUS clinical trials

US Patents and Regulatory Information for APTIVUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	APTIVUS	tipranavir	CAPSULE;ORAL	021814-001	Jun 22, 2005		RX	Yes	Yes
Boehringer Ingelheim	APTIVUS	tipranavir	SOLUTION;ORAL	022292-001	Jun 23, 2008		DISCN	Yes	No

EU/EMA Drug Approvals for APTIVUS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Boehringer Ingelheim International GmbH	Aptivus	tipranavir	EMEA/H/C/000631Aptivus, co-administered with low-dose ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infection in highly pretreated adults and adolescents 12 years of age or older with virus resistant to multiple protease inhibitors.Aptivus should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.This indication is based on the results of two phase-III studies, performed in highly pretreated adult patients (median number of 12 prior antiretroviral agents) with virus resistant to protease inhibitors and of one phase-II study investigating pharmacokinetics, safety and efficacy of Aptivus in mostly treatment-experienced adolescent patients aged 12 to 18 years.In deciding to initiate treatment with Aptivus, co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of Aptivus. Initiation of treatment should take into account the combinations of mutations which may negatively impact the virological response to Aptivus, co-administered with low-dose ritonavir.	Authorised	no	no	no	2005-10-25

International Patents for APTIVUS

See the table below for patents covering APTIVUS around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	236894
Australia	2368699
Australia	2462695
Australia	701965
Australia	718117
Brazil	9507615
Canada	2187523	COMPOSES DE PYRANONE UTILES POUR TRAITER DES INFECTIONS A RETROVIRUS (PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS)

Supplementary Protection Certificates for APTIVUS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0758327	91220	Luxembourg		91220, EXPIRES: 20200504
0758327	PA2005008	Lithuania		PRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327	300216	Netherlands		300216, 20150504, EXPIRES: 20200503
0758327	SPC034/2005	Ireland		SPC034/2005: 20061023, EXPIRES: 20200503
0758327	PA2005008,C0758327	Lithuania		PRODUCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327	C00758327/01	Switzerland		FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0758327	05C0047	France		PRODUCT NAME: TIPRANAVIR; REGISTRATION NO/DATE: EU/1/05/315/001 20051025

Aptivus (tipranavir) market dynamics and financial trajectory: revenue trends, pricing pressure, and generic/biosimilar risk

Last updated: July 24, 2026

Executive summary: Aptivus (tipranavir) is a legacy HIV protease inhibitor with materially shrinking demand driven by guideline displacement (boosted darunavir, atazanavir, and integrase-based regimens), sustained payer preference shifts, and effective loss of exclusivity for key Orange Book-listed patents. Financial trajectory is dominated by volume decline rather than pricing recovery, with ongoing exposure to competitive erosion in liquid forms and procedural switching among salvage-experienced populations. Near-term growth is structurally capped; the competitive battle is now around retention in “tipranavir-experienced” or multi-class resistant subgroups, not new starts.

---

How has Aptivus (tipranavir) revenue changed over time and what drives the financial trajectory?

Core dynamic: Aptivus demand has trended down as HIV therapy moved from protease inhibitor (PI)-centered strategies to integrase strand transfer inhibitor (INSTI)-based regimens and as salvage practice increasingly favors other boosted PIs with better tolerability and higher barriers to resistance.

Primary revenue drivers

• New start displacement: Clinical adoption shifted away from older PI anchors as INSTI regimens expanded first-line and second-line options.
• Salvage cohort shrinkage: The remaining high-value use case is salvage in heavily treatment-experienced patients with resistance patterns where tipranavir regimens remain viable. That cohort size narrows as overall resistance trajectories change and newer classes become standard earlier.
• Tolerability and switching: Tipranavir’s safety and tolerability profile (notably hepatic-related risks and lipid changes) increases switching behavior when alternatives are clinically acceptable.
• Payer formulary pressure: Formularies increasingly optimize for updated guideline-aligned therapies, creating claims friction and net price erosion in smaller remaining patient sets.

Market structure that shapes financial outcomes

• Low-volume, high-friction market: As patients leave the regimen class, the residual market becomes smaller, more payer-constrained, and more sensitive to prior authorization and documentation requirements.
• Retention rather than acquisition: Revenue becomes a function of keeping existing patients, not expanding addressable population.

---

What is the current competitive landscape for Aptivus in HIV protease inhibitor therapy?

Featured competitive set (class and regimen substitutes)

• Boosted PIs with stronger modern positioning: darunavir (boosted with ritonavir or cobicistat, depending on product), atazanavir (boosted), and other boosted PI regimens used in salvage settings.
• INSTI-based combinations: for patients who can use INSTIs, these regimens generally reduce dependence on tipranavir as a salvage PI.
• Other salvage strategies: optimized background regimens that use resistance testing to select active agents, which reduces the probability that tipranavir remains the “must-have” component.

Why this matters for Aptivus economics

• Competitive switching typically reduces market share faster than pricing can compensate.
• Even when tipranavir remains clinically relevant in a subset, it faces claims resistance if payers can obtain comparable efficacy with better convenience and tolerability elsewhere.

---

How do patent expiration and Orange Book status affect Aptivus generics and revenue risk?

High-level exclusivity impact (what to expect)

• When Orange Book-listed formulation and method patents expire, generic entry risk increases and price typically compresses quickly.
• In legacy HIV drugs, generics often arrive after patent cliffs, and even if a residual niche persists, net revenue usually declines sharply due to automatic substitution and payer-driven conversion.

Actionable implication for Aptivus

• The investment and litigation risk profile for a legacy PI shifts from “still protected” to “already exposed,” with revenue trajectory increasingly tied to how quickly substitution reaches the remaining salvage cohort.

(Note: this article does not list specific Orange Book patent numbers or expiry dates because complete patent-by-patent Orange Book extraction is not provided in the prompt. Without the patent dataset, a precise legal status table would risk being inaccurate.)

---

How likely is Paragraph IV litigation or generic entry for Aptivus, and what timelines matter?

Legacy pattern in HIV PI portfolios

• After exclusivity expiration, the first wave is usually generic approval and launch, not necessarily Paragraph IV filing if listed patents are already expired or withdrawn.
• Follow-on risks include:
  • re-litigation over formulation or process patents (if any remain),
  • market entry delays based on patent injunctions or settlement terms,
  • product withdrawals or supply disruptions that can temporarily stabilize prices.

Timeline lens

• Revenue tends to fall in two steps:
  1. pre-launch net price erosion when payers anticipate substitution,
  2. post-launch decline as dispensing moves to generics.

For Aptivus, the key commercial takeaway is that the biggest financial damage historically occurs at the transition from branded coverage to generic substitution, and then stabilizes at a lower run-rate in the remaining medically constrained niche.

---

What is the biosimilar risk profile for Aptivus (tipranavir), and how does it differ from biologics?

Aptivus is a small-molecule drug. Biosimilar frameworks do not apply because biosimilars track biologic references (mAbs, cytokines, fusion proteins). Competitive pressure is thus limited to chemical generics and possible non-infringing authorized supply arrangements rather than biosimilar switching.

---

What formulations and delivery systems affect Aptivus market adoption (capsules vs oral solution)?

Aptivus is used in a dosing format that supports oral administration in salvage settings, including patients with treatment constraints that can influence preference for certain formulations.

Economic effect

• Formulation-specific coverage: Some payers and formularies assign different tiers or require prior authorization differently by dosage form.
• Switching frictions: Patients stable on one formulation may resist a change unless the alternative is therapeutically equivalent and coverage is clear.
• Manufacturing and supply continuity: In legacy markets, supply stability can temporarily influence pricing because shortages can limit substitution.

---

How does Aptivus compare with other HIV protease inhibitors on market access and payer placement?

Typical payer logic

• Payers often prefer drugs with:
  • simpler monitoring,
  • lower acute adverse event burden,
  • better medication convenience,
  • fewer drug-drug interaction concerns in common co-medications,
  • strong guideline support.

Competitive comparison outcome

• Newer PI positioning and INSTI dominance compress the addressable market for tipranavir.
• Aptivus’s advantage is narrower and mostly clinical: it can fit specific resistance-driven scenarios. That reduces net monetization versus earlier years when it was a broader regimen choice.

---

What regulatory pathway dynamics influence Aptivus availability and generic substitution?

For small-molecule HIV drugs:

• FDA approval of generics under ANDA is the primary mechanism for substitution.
• Label equivalence and bioequivalence support interchangeability.
• If any formulation or method-of-use patents remain enforceable, they can delay approval or launch, but post-expiry the bottleneck is primarily patent status and injunctions rather than regulatory science barriers.

Commercial implication

• Even when FDA approval is obtained, payer coverage and pharmacy benefit design determine the pace of market conversion. That is where legacy HIV economics diverge: medical relevance does not always translate into formulary placement.

---

How do pricing, rebates, and net price erosion typically evolve for legacy branded HIV drugs like Aptivus?

Net revenue drivers after new competition

• Rebate intensity rises: As formulary pressure increases, branded manufacturers often raise rebates to protect placement.
• AMP and negotiated discounts compress: Generic entry causes rapid negotiated discount recalibration.
• Mix shift: Even if total scripts decline, the payer mix can shift from commercial to covered managed care segments that negotiate more aggressively.

Expected financial pattern

• Branded revenue typically declines faster than costs can adjust because supply chain and support functions do not fall in proportion to shrinking demand.
• Profitability therefore weakens unless the company has offsetting portfolio performance or supply-cost advantages.

---

Which segments still support Aptivus demand, and how does that affect long-run earnings stability?

Demand pockets

• Heavily treatment-experienced patients where resistance testing supports tipranavir use.
• Patients with limited alternatives based on resistance pattern and prior exposure history.

Earnings stability implication

• These pockets support a lower but more predictable base if formulary carve-outs or prior authorization pathways remain stable.
• Revenue stability is conditional: one competitor protocol change, a new guideline preference, or a payer policy update can accelerate declines.

---

What litigation and settlement events historically shape legacy HIV branded economics?

In the HIV small-molecule space, legal risk typically affects revenue through:

• Launch delay (if injunctions apply),
• Settlement-driven market entry timing (early generic launch at a contracted date),
• Exclusion or limited distribution (sometimes structured through supply arrangements).

For Aptivus specifically

• The prompt does not provide litigation dockets, settlement terms, or patent identifiers. A litigation timeline cannot be stated accurately without that dataset.

---

Aptivus financial trajectory vs. key HIV competitors: what tends to differ?

What usually diverges across legacy competitors

• Timing of generic substitution after patent cliffs.
• Strength of remaining niche indications and clinician familiarity.
• Presence of alternative branded products with better payer pull in the same cohort.

Where Aptivus typically underperforms

• Market relevance declines as treatment pathways become more INSTI-centered.
• PI competition consolidates around preferred boosted PIs with better perceived tolerability and formulary acceptance.

---

Key Takeaways

• Aptivus (tipranavir) faces structurally declining demand driven by guideline displacement and salvage-cohort narrowing.
• Revenue trajectory is dominated by volume loss and payer-driven net price erosion, not new patient growth.
• Generic substitution risk becomes the principal long-term commercial threat once remaining exclusivity blocks clear.
• Because Aptivus is a small molecule, competitive risk is primarily ANDA-based generic entry, not biosimilar competition.
• Long-run earnings stability depends on retention in resistance-defined salvage niches and on how fast payers convert to substitutes after exclusivity windows close.

---

FAQs

1) What are the biggest commercial drivers of Aptivus script declines?
Guideline shift toward INSTI-based regimens, salvage cohort shrinkage, tolerability-related switching, and payer formulary pressure.

2) Does Aptivus face biosimilar competition?
No. It is a small-molecule drug; competition comes from chemical generics, not biosimilars.

3) What happens to branded HIV drug net revenue when generics enter?
Net price typically compresses quickly due to higher rebate pressure and payer switching, causing a steep revenue drop even if some patients remain clinically constrained.

4) Which dosing form factors can influence payer coverage for Aptivus?
Formulation-specific formulary placement, prior authorization requirements, patient stability on a given dosage form, and supply continuity.

5) How do patent expirations translate into real-world market share losses?
They increase generic approval and launch probability; the pace of substitution then depends on payer benefit design, pharmacy conversion, and any remaining enforceable patents.

---

References (APA)

1. FDA. (n.d.). Drugs@FDA: Aptivus (tipranavir). U.S. Food and Drug Administration.
2. FDA. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.

(No further sources were used because the prompt did not include specific revenue/financial filings, patent lists, or litigation records for Aptivus.)